GET DAILY SIGNALSWhy Is Armata Pharmaceuticals (ARMP) Stock Up 4.03% Today?
Key Takeaways
- ARMP climbed 4.03%, or $0.15, to $3.87 in Friday morning trading, rebounding from Thursday's 4.37% slide.
- The primary catalyst was the company's third-quarter 2026 report, released after Thursday's close, which showed a narrower loss and revenue well above consensus.
- Revenue of $3.17 million beat estimates of roughly $450,000, while the loss of $0.24 per share came in far better than the $0.41 consensus.
- Results were flattered by a $69.6 million non-cash gain on the fair value of the company's convertible loan, so reported net income overstates operating progress.
- The stock remains below both its 50-day and 200-day moving averages after touching a 52-week low near $2.75 earlier this month.
- News Significance Score: 25/100 — a routine quarterly beat produced an unremarkable move for a stock that swings more than 5% on a typical day.
- Investors will focus on the 4:00 p.m. ET earnings call and management's timeline for the AP-SA02 Phase 3 program.
- Deeper detail on Price Targets, Earnings, and Forecast pages is available for readers who want to go beyond the headline numbers.
- Readers can also explore the Trending AI Robots page to see which automated strategies are performing best in the current market.
Opening Summary
Armata Pharmaceuticals, Inc. (ARMP) is a Los Angeles-based, late clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections. Its lead candidate, AP-SA02, targets complicated Staphylococcus aureus bacteremia and carries Qualified Infectious Disease Product, Fast Track, and Breakthrough Therapy designations from the FDA. The company is majority-owned by Innoviva (INVA).
Shares traded at $3.87 on Friday morning, up $0.15, or 4.03%, from Thursday's close of $3.72. The direction is firmly positive, and the immediate reason is clear: Armata's third-quarter results, published after Thursday's closing bell, beat consensus on both revenue and earnings.
Third-Quarter Beat Reverses Thursday's Slide
Armata reported a third-quarter net loss of $0.24 per share on a diluted basis, comfortably better than the loss of about $0.41 that analysts had modeled. Revenue of $3.17 million compared with a consensus estimate near $450,000 and with $1.16 million a year earlier, a 173% increase.
Thursday's regular-session decline of 4.37% occurred before the release, leaving room for a corrective bounce once the numbers were in hand. The stock had also traded modestly higher in Thursday's after-hours session, and Friday's move extends that post-report drift. For a company of this size, the beat was meaningful enough to justify a modest relief rally, though not enough to reset the broader narrative.
Revenue Beat Built on Funding, Not Product Sales
Much of the revenue upside stems from non-dilutive government support rather than commercial traction. Armata has received roughly $32.4 million in total funding from the U.S. Department of War for the AP-SA02 program, including a $3.7 million addition announced earlier this year. Investors should read the revenue beat as validation of program funding, not as evidence of product demand.
The profit line is similarly optical. Reported net income of $54.9 million was driven almost entirely by a $69.6 million gain from the change in fair value of the company's convertible loan. Cash and equivalents stood at $18.3 million at September 30, up from $8.7 million at the end of 2025 — an improvement, but modest against a liability stack that includes a $94.3 million current convertible loan and $83.9 million of current term debt.
Market Context and Trading Activity
The advance was company-specific. No sector-wide catalyst was evident, and the reaction tracked the earnings release rather than any broad biotechnology move.
Liquidity is thin: roughly 182,000 shares change hands on an average session, and Thursday's turnover of about 105,000 shares was already below that pace. With approximately 37.2 million shares outstanding and a market capitalization near $144 million, relatively small order flow can move the quote by several percentage points.
Technically, the stock is recovering from a 52-week low near $2.75 reached in early November and has now gained roughly 29% from its November 5 close of $3.00. It still trades below its 50-day moving average, near $4.10, and well below its 200-day average, near $6.95. The 52-week high of $14.98 underscores how far the shares have retraced over the past year.
News Significance Score
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Armata's score is 25 out of 100.
The verified news was moderate: a quarterly beat on both lines, but one powered partly by government grant revenue and a non-cash accounting gain, and consistent with a company that has beaten consensus in four of the last eight quarters. The price move was unremarkable by the stock's own standards — today's 4.03% gain is smaller than the average absolute daily move of about 5.4% over the past 60 sessions, and moves of that size or larger occurred more than 30 times in that window. A modest catalyst plus a routine move produces a low score.
What Comes Next for ARMP
Management hosts its third-quarter conference call on Friday at 4:00 p.m. ET, where commentary on the AP-SA02 Phase 3 timeline will matter more than the reported figures. The company has said the superiority study in complicated S. aureus bacteremia is expected to begin in the second half of 2026, with exact timing dependent on FDA agreement on the protocol.
Analyst coverage is thin, with two firms publishing ratings and a wide dispersion in targets. Consensus revenue forecasts imply lumpy, grant-dependent top-line results, and the December quarter is expected to show a sequential decline. Risks include the current liability stack, a stockholders' deficit of roughly $174 million, the need for additional capital before a potential BLA submission, and the binary nature of a Phase 3 readout in an unproven therapeutic class. Trial initiation news, FDA correspondence, and any financing activity are the events most likely to drive the next significant repricing.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, and only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the list changes as market conditions shift. Reviewing the page regularly can help investors see which automated approaches are keeping pace with today's volatility. Explore the current leaders and compare their track records.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ARMP's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ARMP turned positive on October 20, 2026. Looking at past instances where ARMP's MACD turned positive, the stock continued to rise in 42 of 47 cases over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARMP's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ARMP as a result. In 90 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +26.67% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARMP advanced for three days, in 218 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
ARMP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
ARMP moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ARMP entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.565) is normal, around the industry mean (3.498). P/E Ratio (-0.664) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. ARMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel bacteriophage-based therapeutics
Industry Biotechnology
Advertisement